Human skin is far more than a physical barrier. Its surface area of approximately 2 m² — expanding to an estimated 25 m² when hair follicles, sebaceous glands, and sweat glands are included — forms a complex ecosystem in which billions of microorganisms interact continuously and dynamically with the skin's chemical environment. Lipids are at the center of this interaction. Sebaceous gland density in lipid-rich zones can reach up to ~900 glands per cm², and their secretion — sebum, rich in triglycerides, wax esters, and squalene — is the primary energy source for the skin's lipophilic inhabitants.

For a long time, researchers viewed this relationship as largely one-directional: the lipid composition of the skin determines which microorganisms can survive on it. Accumulating evidence tells a different story. The influence is bidirectional, and the microorganisms themselves are active processors and producers of lipid molecules.

The review by Sylvia B. Khalil and Caitlin H. Kowalski, published in June 2026 in mSphere, set out to synthesize current knowledge on how skin-resident microbes access host lipids, transform them, and produce their own — and what this means for skin health [1]. The work draws on studies employing metagenomics, metatranscriptomics, imaging mass spectrometry, propidium monoazide (PMA)-based sequencing, and gnotobiotic animal models — tools that for the first time enable high-resolution analysis of the "live" metabolism of the skin microbial community. Here are the key findings.

How microbes use skin lipids

Skin surface lipids originate from two sources: sebaceous glands (sebum) and the stratum corneum, where ceramides, cholesterol, and free fatty acids (FFAs) are synthesized. A telling detail: 95% of FFAs on the skin surface derive from sebum, and only 5% from the stratum corneum. These acids serve as the primary nutritional substrate for lipophilic bacteria — most notably Cutibacterium acnes and members of the genus Corynebacterium.

The mechanism is straightforward but biologically consequential: bacteria secrete lipases that hydrolyze sebum triglycerides into FFAs. From there, fine-grained biochemistry takes over. C. acnes ferments fatty acids to yield propionic, acetic, and other short-chain fatty acids (SCFAs), acidifying the skin surface to around pH 5 — a range that in itself suppresses the growth of many pathogens. Sapienic acid (C16:1, Δ6) — a human-specific FFA produced by sebaceous glands — exhibits potent antimicrobial activity against Staphylococcus aureus. Microbial transformation of this molecule directly modulates that activity.

The microbiome as an active lipid synthesizer

The central conceptual contribution of this review is that the microbiome's relationship with lipids is not one-way consumption: microorganisms generate fundamentally new lipid molecules, reshaping the skin's chemical environment. Commensal Staphylococcus epidermidis has been shown to synthesize protective ceramides that strengthen skin barrier function [2]. Fungi of the skin mycobiome convert stearic acid into 10-hydroxystearic acid — a molecule with demonstrated antagonistic activity against S. aureus [4]. SCFAs produced by skin bacteria modulate the epidermal immune response by inhibiting histone deacetylases (HDAC8 and HDAC9), thereby reducing tolerance to Toll-like receptor (TLR) ligands.

Not all microbial lipid activity serves the host. S. aureus actively scavenges oleic acid from its environment. It is incorporated into membrane phospholipids: lysyl-phosphatidylglycerol (Lysyl-PG) can account for 20–40% of the staphylococcal membrane phospholipid content, thereby reducing bacterial susceptibility to host antimicrobial peptides. The implication is clear: the skin's lipid composition is not a neutral backdrop — it is a direct determinant of bacterial pathogenicity.

A metatranscriptomic study published in Nature Biotechnology in 2025 [5] demonstrated that the transcriptional activity of skin microbes varies substantially by anatomical site. This points to differing metabolic demands on the lipid pool in sebaceous-rich, moist, and dry skin zones — and helps explain why the microbiome–lipid axis operates differently on the face, body, and scalp.

Links to dermatological disease

Disruptions of the microbiome–lipid axis are associated with several common skin conditions. In acne, overactivity of C. acnes and an imbalanced composition of sebum lipids drive the inflammatory cascade. In atopic dermatitis (AD), protective ceramide synthesis is impaired, and SCFA production is reduced — changes linked to deficiency or dysfunction of commensal staphylococci [3]. In dandruff and seborrheic dermatitis, Malassezia species hydrolyze sebum and release irritant unsaturated fatty acids.

The authors emphasize that the relationship between shifts in lipid profiles and dysbiosis is bidirectional — distinguishing primary from secondary disruption is rarely straightforward in clinical practice.

Limitations

The authors identify several important limitations in the current evidence base. Most mechanistic data come from cell culture or animal model experiments; human clinical studies are often associative and cannot establish causality. Standard metagenomics identifies microbial presence but not actual metabolic activity; metatranscriptomics partially addresses this gap but has not yet become a routine tool. PMA-based sequencing allows differentiation of viable from non-viable bacteria but remains confined to research settings. Finally, skin lipid composition varies considerably with age, sex, anatomical site, and genetic background, limiting direct extrapolation of experimental findings to clinical practice.

Therapeutic strategies: from biology to practice

The authors outline four concrete directions for applying knowledge of the microbiome–lipid axis.

1. Prebiotic approach: Topical application of lipid precursors or substrates preferentially utilized by commensal microorganisms can selectively support beneficial species while suppressing pathogens. This principle is already partially embedded in several skincare formulations marketed as "microbiome-friendly."
2. Probiotic approach: Topical transplantation of live lipid-producing or lipid-transforming microorganisms. A notable example is the use of Roseomonas mucosa in AD: clinical studies have demonstrated disease improvement, at least in part attributable to normalization of lipid metabolism.
3. Postbiotics and direct application of purified lipid compounds: Butyrate derivatives are being investigated as antimicrobial agents against S. aureus; antagonistically active modified fatty acids produced by mycobiome fungi [4] may also serve as a basis for topical drug development.
4. Biomarker potential: Analysis of volatile lipid compounds in sebum opens unexpected diagnostic avenues. Eicosane concentration in sebum, for instance, is being studied as a potential biomarker for Parkinson's disease — an illustration that the skin lipidome may reflect not only local but also systemic processes.

For the practicing skincare specialist, the practical takeaway is clear: the composition of topically applied products — particularly those containing fatty acids, oils, ceramides, and emollients — can influence the microbial landscape. That influence can be either protective or destabilizing, depending on the specific formulation and the patient's baseline microbiome.

Conclusion

The skin microbiome is an active metabolic partner — one that reads the skin's lipid composition and rewrites it according to its own logic. This review provides a conceptual framework for understanding that axis and identifies specific intervention points for new strategies, ranging from personalized topical formulations to microbial transplantation.

Recognizing that every lipid applied to the skin is a potential signal to the microbial community introduces a new dimension for skincare practitioners working with barrier-supportive, microbiome-friendly products. The next step is translating these findings into clinical protocols — a task that will require larger, rigorously controlled human studies.

References

1. Khalil S.B., Kowalski C.H. The cutaneous microbiome: microbial remodeling of the skin lipid landscape. mSphere 2026; 0(0): e00648-25.
2. Zheng Y., Hunt R.L., Villaruz A.E. et al. Commensal Staphylococcus epidermidis contributes to skin barrier homeostasis by generating protective ceramides. Cell Host Microbe 2022; 30: 301–313.
3. Nakatsuji T., Chen T.H., Narala S. et al. Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus and are deficient in atopic dermatitis. Sci Transl Med 2017; 9: eaah4680.
4. Kowalski C.H., Nguyen U.T., Lawhorn S.et al. Skin mycobiota-mediated antagonism against Staphylococcus aureus through a modified fatty acid. Curr Biol 2025; 35: 2266–2281.
5. Chia M., Ng A.H.Q., Ravikrishnan A. et al. Skin metatranscriptomics reveals a landscape of variation in microbial activity and gene expression across the human body. Nat Biotechnol 2025 Aug 28. doi: 10.1038/s41587-025-02797-4. Epub ahead of print.